HomeBusinessWatch
MLM Companies

Immunotec Review 2026

Glutathione supplement MLM where 75% earn nothing

2.0

HomeBusinessWatch Rating

Last updated: March 20, 2026

What is Immunotec?

Nutritional supplements focused on glutathione enhancement through Immunocal — a patented whey protein isolate. Based on research by Dr. Gustavo Bounous. Products marketed for immune health and cellular function support.

Pros

  • Unique patented product (Immunocal) with scientific research behind it
  • Company pays no commission for recruiting alone — only product sales
  • Long-established company since 1996
  • Based on legitimate glutathione research by Dr. Gustavo Bounous

Cons

  • 75% of consultants earn no income according to 2022 income disclosure
  • Only 2.2% earn more than $1,000/month on average
  • DSSRC expressed concern over income claims suggesting significant earnings
  • No longer accredited by Better Business Bureau
  • High ongoing costs to remain active ($45+ monthly)

Rating Breakdown

Residual Income
1.5

Potential for ongoing passive income

Simplicity
2.0

Easy to understand and execute

Transparency
2.0

Clear about costs, requirements, and income

Community & Support
2.5

Quality of training and community

Value for Money
2.0

Worth the investment

Overall Rating
2.0

Frequently Asked Questions About Immunotec

Does Immunotec work?
Immunocal is based on legitimate glutathione research by Dr. Gustavo Bounous. The product may support glutathione levels, though health claims are not FDA-evaluated. However, similar supplements are available at lower prices outside the MLM structure.
How much do Immunotec consultants earn?
According to the 2022 income disclosure, 75% of consultants earn no income at all. Only 2.2% earn more than $1,000 per month. Factoring in the $45+ monthly costs to remain active, most consultants lose money.
Is Immunotec accredited by the BBB?
No — Immunotec is no longer accredited by the Better Business Bureau, raising concerns about the company's commitment to transparency and trustworthiness. The DSSRC has also raised concerns about income claims.